Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Want to cut your energy bills? Here’s how five experts are doing it 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
WILMINGTON, Del., March 11, 2016 -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of Horizon Pharma plc (NASDAQ:HZNP)?
- Did you purchase your shares between March 13, 2014 and February 26, 2016, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. announces that a complaint has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities that purchased the common stock of Horizon Pharma plc (“Horizon” or the “Company”) (NASDAQ:HZNP) between March 13, 2014 and February 26, 2016, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
If you purchased shares of Horizon during the Class Period, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to [email protected]; or at: http://rigrodskylong.com/investigations/horizon-pharma-plc-hznp-lawsuit.
The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects. As a result of defendants’ alleged false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period.
According to the Complaint, on February 29, 2016, Horizon revealed that in November 2015, the Company had received a subpoena from the U.S. Attorney’s Office for the Southern District of New York requesting documents and information related to its patient assistance programs and other aspects of its marketing and commercialization activities.
On this news, shares of Horizon dropped over 13%, closing at $17.16 per share on February 29, 2016, on heavy trading volume.
If you wish to serve as lead plaintiff, you must move the Court no later than May 9, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com
